Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, MasterCard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
tag
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
TME

Prezzo Tencent Music

TME
$9,73
+$0,30(+3,18%)

*Data last updated: 2026-04-15 08:05 (UTC+8)

As of 2026-04-15 08:05, Tencent Music (TME) is priced at $9,73, with a total market cap of $14,92B, a P/E ratio of 17,47, and a dividend yield of 2,51%. Today, the stock price fluctuated between $9,53 and $9,93. The current price is 2,09% above the day's low and 2,01% below the day's high, with a trading volume of 9,95M. Over the past 52 weeks, TME has traded between $8,78 to $26,70, and the current price is -63,55% away from the 52-week high.

TME Key Stats

Yesterday's Close$9,43
Market Cap$14,92B
Volume9,95M
P/E Ratio17,47
Dividend Yield (TTM)2,51%
Dividend Amount$0,23
Diluted EPS (TTM)3,57
Net Income (FY)$10,75B
Revenue (FY)$32,00B
Earnings Date2026-05-12
EPS Estimate0,21
Revenue Estimate$1,14B
Shares Outstanding1,58B
Beta (1Y)0.786
Ex-Dividend Date2026-04-02
Dividend Payment Date2026-04-23

About TME

Tencent Music Entertainment Group operates online music entertainment platforms to provide music streaming, online karaoke, and live streaming services in the People's Republic of China. It offers QQ Music, Kugou Music, and Kuwo Music that enable users to discover and listen to music in personalized ways; and WeSing, which enables users to have fun by singing and interacting with friends, sharing their singing performances with friends, and discovering songs that others have sung. The company also operates Kugou Music, Kuwo Music, WeSing, QQ Music, Kugou Live, and Kuwo Live that provides an interactive online stage for performers and users to showcase their talent and engage with those interested in their performance; and Kuwo Changting, an audio platform that offers users various audio content, including audio books, cross-talks, radio dramas, and other entertainment. In addition, it sells music-related merchandise, including Kugou headsets, smart speakers, WeSing karaoke microphones, and Hi-Fi systems; and offers online music event ticketing services, as well as services to smart device and automobile makers to build and operate music services on devices and vehicles. Tencent Music Entertainment Group has a strategic partnership with China Literature. The company is headquartered in Shenzhen, China. Tencent Music Entertainment Group is a subsidiary of Tencent Holdings Limited.
SectorCommunication Services
IndustryInternet Content & Information
CEOZhu Liang
HeadquartersShenzhen,None,CN
Official Websitehttps://www.tencentmusic.com
Employees (FY)100,00K
Average Revenue (1Y)$320,05K
Net Income per Employee$107,54K

Tencent Music (TME) FAQ

What's the stock price of Tencent Music (TME) today?

x
Tencent Music (TME) is currently trading at $9,73, with a 24h change of +3,18%. The 52-week trading range is $8,78–$26,70.

What are the 52-week high and low prices for Tencent Music (TME)?

x

What is the price-to-earnings (P/E) ratio of Tencent Music (TME)? What does it indicate?

x

What is the market cap of Tencent Music (TME)?

x

What is the most recent quarterly earnings per share (EPS) for Tencent Music (TME)?

x

Should you buy or sell Tencent Music (TME) now?

x

What factors can affect the stock price of Tencent Music (TME)?

x

How to buy Tencent Music (TME) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

TME
CFD
Fai trading

Hot Posts su Tencent Music (TME)

SelfRugger

SelfRugger

04-11 09:35
This is a paid press release. Contact the press release distributor directly with any inquiries. ![](https://img-cdn.gateio.im/social/moments-676639657a-7e391e2043-8b7abd-d8d215) Summit Therapeutics to Present at Upcoming Investor Conferences =============================================================== Business Wire Fri, February 27, 2026 at 8:45 AM GMT+9 9 min read In this article: SMMT +0.77% ![](https://img-cdn.gateio.im/social/moments-e8874b0649-00cfc75fe1-8b7abd-d8d215) **MIAMI, February 26, 2026**--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: * TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 * Fireside chat 2:30pm ET * Jefferies Conference in Miami on Tuesday, March 10, 2026 * _Investor meetings only_ * Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026 * Fireside chat 2:15pm ET The fireside chats will be available live on our website: www.smmttx.com. An archived version of both presentations will be available on our website following the presentation. **About Ivonescimab** Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF. This is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. We believe ivonescimab’s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, _iScience_, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, _iScience_, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets. Ivonescimab was engineered by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 4,000 patients have been treated with ivonescimab in clinical studies globally, and over 60,000 patients when considering those treated in a commercial setting in China, as noted by Akeso. Story Continues There are currently 15 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, four of which are Summit-sponsored global studies, one of which is a multiregional study sponsored by a cooperative group, and ten of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC, commencing enrollment in 2023 in two multiregional Phase III clinical trials, HARMONi and HARMONi-3. In 2025, the Company began enrolling patients in HARMONi-7. Summit expanded its Phase III clinical development program into CRC in the fourth quarter of 2025 by initiating enrollment in HARMONi-GI3. HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI (e.g., osimertinib). Detailed results of the study were provided in September 2025, and a Biologics License Application (BLA) was submitted to the United States Food and Drug Administration (FDA) for marketing authorization, which the FDA accepted for filing in January 2026; the goal Prescription Drug User Fee Act (PDUFA) date is November 14, 2026. HARMONi-3 is a Phase III clinical trial, which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous or non-squamous NSCLC, irrespective of PD-L1 expression. HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression. HARMONi-GI3 is a Phase III clinical trial evaluating ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy in patients with first-line unresectable metastatic CRC. Also including Summit’s license territories, a Phase III study is planned to be conducted by GORTEC, a cooperative group dedicated to Head and Neck Oncology, in recurrent / metastatic head and neck squamous cell carcinoma (r/m HNSCC). ILLUMINE is a three-arm Phase III clinical trial which is intended to evaluate ivonescimab monotherapy, as well as ivonescimab in combination with ligufalimab, Akeso’s proprietary anti-CD47 monoclonal antibody, compared to monotherapy pembrolizumab in patients with PD-L1 positive r/m HNSCC. In addition, Akeso has recently had positive read-outs in three single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, and HARMONi-6, for ivonescimab in NSCLC, including a statistically significant overall survival benefit in HARMONi-A with a manageable safety profile in each study. HARMONi-A was a Phase III clinical trial which evaluated ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with an EGFR TKI. HARMONi-2 is a Phase III clinical trial evaluating monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression. HARMONi-6 is a Phase III clinical trial evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous NSCLC, irrespective of PD-L1 expression. Akeso is actively conducting multiple Phase III clinical studies in settings outside of NSCLC, including biliary-tract cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer. Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US FDA for the HARMONi clinical trial setting. **About Summit Therapeutics** Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol "SMMT"). We are headquartered in Miami, Florida, and we have additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK. For more information, please visit https://www.smmttx.com and follow us on X @SMMT_TX. **Summit Forward-looking Statements** Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc., the intended use of the net proceeds from the private placements, the Company's anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program ("ATM Program"), the expected proceeds and uses thereof, the Company’s estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a "positive study" as a clinical study that with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. Summit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics Inc. and/or its affiliates. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260226560754/en/ **Contacts** **Contact Summit Investor Relations: ** Dave Gancarz Chief Business & Strategy Officer Nathan LiaBraaten Senior Director, Investor Relations investors@smmttx.com media@smmttx.com Terms and Privacy Policy Privacy Dashboard More Info
1
0
0
0
ForkLibertarian

ForkLibertarian

04-08 04:27
Stock Market Update for the Trading Week Ended March 20 ------------------------------------------------------- * The Morningstar US Market Index fell 1.82%. * The best-performing sectors were energy, up 2.99%, and financial services, up 0.35%. * The worst-performing sectors were utilities, down 5.0%, and basic materials, down 4.82%. * Large-cap stocks fell 2.0%, mid-cap stocks fell 1.26%, and small-cap stocks fell 1.64%. * Growth stocks fell 1.71%, blend stocks fell 1.63%, and value stocks fell 1.54%. * The S&P 500 fell 1.9% and the Nasdaq fell 2.07%. * Of the 837 US-listed companies covered by Morningstar, 270, or 32%, were up, two were unchanged, and 565, or 68%, were down. Bonds and Commodities --------------------- * Yields on 10-year US Treasury notes rose to 4.39% from 4.28%. * Yields on 2-year US Treasury notes rose to 3.88% from 3.73%. * West Texas Intermediate crude prices fell 1.69% to $97.63 per barrel. * Comex Gold prices fell 10.23% to $4,507.20. Top Stock Gainers ----------------- SolarEdge Technologies SEDG, Venture Global LNG VG, Equinor EQNR, Tandem Diabetes Care TNDM, and Arm Holdings ARM were the top performers among US-listed stocks covered by Morningstar analysts. * SolarEdge topped the list, rising 38.06%, and it’s up 57.12% over the past three months. This no-moat company with a 3-star rating has increased 168.90% over the past 12 months. The stock closed the week at $51.69, trading at a 27% premium to its fair value estimate of $36.00 per share. * Venture Global was the second-best performer, with a weekly return of 20.4%. The 2-star stock has gained 125.32% over the last three months. Shares in this no-moat company are up 28.2% over the past 12 months. Venture Global stock wrapped up the week at $15.76, trading at a 30% premium to its fair value estimate of $11.00 per share. * Equinor ranked third for the week, with its stock rising 18.05%. The 2-star, no-moat stock has gained 79.14% over the last three months and 66.96% over the past 12. Equinor stock closed at $41.60, trading at a 49% premium to its fair value estimate of $27.20 per share. * The fourth-best-performing stock was no-moat Tandem, which gained 14.96%. The 3-star stock has gained 11.60% over the last three months and is up 19.45% over the past 12. Tandem finished the week at $24.82, trading at a 23% premium to its fair value estimate of $20.00 per share. * Arm stock climbed 14.41% in the latest week. This wide-moat company has seen an increase of 13.85% over the last three months and a rise of 10.10% over the past 12 months. The 1-star stock ended the week at $132.43 per share, trading at a 62% premium to its fair value estimate of $80.00. Top Stock Losers ---------------- Tencent Music Entertainment Group TME, Klarna Group KLAR, Mosaic Company MOS, Sabre SABR and VNET Group VNET did the worst among US-listed stocks covered by Morningstar analysts. * Tencent Music was the worst-performing stock of the week, falling 28.94%. This 5-star, narrow-moat company has fallen 42.16% over the past three months and fell 28.82% over the past 12 months. The stock ended the week at $10.09, trading at a 63% discount to its fair value estimate of $28 per share. * Klarna took the second spot, with a 20.79% decline this week. The narrow-moat company, rated 5 stars, has fallen 56.43% over the past three months. Closing at $12.61, the stock trades at a 70% discount to its fair value estimate of $45.00 per share. * Mosaic came in third, experiencing a 19.49% drop this week. This 4-star, no-moat company has risen 11.01% over the past three months but fell 3.18% over the past 12 months. The stock finished the week at $23.59, trading at a 34% discount to its fair value estimate of $40.00 per share. * Next up is Sabre, which saw its price fall by 17.5% this week. The no-moat company with a 4-star rating has fallen 5.07% over the past three months and is down 60.53% over the past 12. At $1.32, the stock trades at a 30% discount to its fair value estimate of $2.02 per share. * VNET rounds out the list with a 16.08% decline this week. This 2-star, no-moat company has risen 6.97% over the past three months but fell 4.97% over the past 12 months. The stock closed the week at $8.82, trading at a 25% premium to to its fair value estimate of $7.50 per share. Highlights of This Week’s Market and Investing Events ----------------------------------------------------- * **Monday, March 23: **January Construction Spending (month to month) * **Thursday, March 26: **Initial Unemployment Insurance Claims report for the week ended March 21
0
0
0
0
ForkLibertarian

ForkLibertarian

04-07 03:26
Stock Market Update for the Trading Week Ended March 20 ------------------------------------------------------- * The Morningstar US Market Index fell 1.82%. * The best-performing sectors were energy, up 2.99%, and financial services, up 0.35%. * The worst-performing sectors were utilities, down 5.0%, and basic materials, down 4.82%. * Large-cap stocks fell 2.0%, mid-cap stocks fell 1.26%, and small-cap stocks fell 1.64%. * Growth stocks fell 1.71%, blend stocks fell 1.63%, and value stocks fell 1.54%. * The S&P 500 fell 1.9% and the Nasdaq fell 2.07%. * Of the 837 US-listed companies covered by Morningstar, 270, or 32%, were up, two were unchanged, and 565, or 68%, were down. Bonds and Commodities --------------------- * Yields on 10-year US Treasury notes rose to 4.39% from 4.28%. * Yields on 2-year US Treasury notes rose to 3.88% from 3.73%. * West Texas Intermediate crude prices fell 1.69% to $97.63 per barrel. * Comex Gold prices fell 10.23% to $4,507.20. Top Stock Gainers ----------------- SolarEdge Technologies SEDG, Venture Global LNG VG, Equinor EQNR, Tandem Diabetes Care TNDM, and Arm Holdings ARM were the top performers among US-listed stocks covered by Morningstar analysts. * SolarEdge topped the list, rising 38.06%, and it’s up 57.12% over the past three months. This no-moat company with a 3-star rating has increased 168.90% over the past 12 months. The stock closed the week at $51.69, trading at a 27% premium to its fair value estimate of $36.00 per share. * Venture Global was the second-best performer, with a weekly return of 20.4%. The 2-star stock has gained 125.32% over the last three months. Shares in this no-moat company are up 28.2% over the past 12 months. Venture Global stock wrapped up the week at $15.76, trading at a 30% premium to its fair value estimate of $11.00 per share. * Equinor ranked third for the week, with its stock rising 18.05%. The 2-star, no-moat stock has gained 79.14% over the last three months and 66.96% over the past 12. Equinor stock closed at $41.60, trading at a 49% premium to its fair value estimate of $27.20 per share. * The fourth-best-performing stock was no-moat Tandem, which gained 14.96%. The 3-star stock has gained 11.60% over the last three months and is up 19.45% over the past 12. Tandem finished the week at $24.82, trading at a 23% premium to its fair value estimate of $20.00 per share. * Arm stock climbed 14.41% in the latest week. This wide-moat company has seen an increase of 13.85% over the last three months and a rise of 10.10% over the past 12 months. The 1-star stock ended the week at $132.43 per share, trading at a 62% premium to its fair value estimate of $80.00. Top Stock Losers ---------------- Tencent Music Entertainment Group TME, Klarna Group KLAR, Mosaic Company MOS, Sabre SABR and VNET Group VNET did the worst among US-listed stocks covered by Morningstar analysts. * Tencent Music was the worst-performing stock of the week, falling 28.94%. This 5-star, narrow-moat company has fallen 42.16% over the past three months and fell 28.82% over the past 12 months. The stock ended the week at $10.09, trading at a 63% discount to its fair value estimate of $28 per share. * Klarna took the second spot, with a 20.79% decline this week. The narrow-moat company, rated 5 stars, has fallen 56.43% over the past three months. Closing at $12.61, the stock trades at a 70% discount to its fair value estimate of $45.00 per share. * Mosaic came in third, experiencing a 19.49% drop this week. This 4-star, no-moat company has risen 11.01% over the past three months but fell 3.18% over the past 12 months. The stock finished the week at $23.59, trading at a 34% discount to its fair value estimate of $40.00 per share. * Next up is Sabre, which saw its price fall by 17.5% this week. The no-moat company with a 4-star rating has fallen 5.07% over the past three months and is down 60.53% over the past 12. At $1.32, the stock trades at a 30% discount to its fair value estimate of $2.02 per share. * VNET rounds out the list with a 16.08% decline this week. This 2-star, no-moat company has risen 6.97% over the past three months but fell 4.97% over the past 12 months. The stock closed the week at $8.82, trading at a 25% premium to to its fair value estimate of $7.50 per share. Highlights of This Week’s Market and Investing Events ----------------------------------------------------- * **Monday, March 23: **January Construction Spending (month to month) * **Thursday, March 26: **Initial Unemployment Insurance Claims report for the week ended March 21
0
0
0
0